Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
about
Unmet Needs in LDL-C Lowering: When Statins Won't Do!Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature reviewLDL cholesterol, statins and PCSK 9 inhibitorsCurrent therapies for lowering lipoprotein (a)Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer proteinCholesterol in the retina: the best is yet to come.Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteersClinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BLiver histology during Mipomersen therapy for severe hypercholesterolemiaMipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization.Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosisFamilial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and ManagementMTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study.PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.The Mechanisms Underlying the Hypolipidaemic Effects of Grifola frondosa in the Liver of Rats.Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.Efficacy and Safety of Lomitapide in Hypercholesterolemia.MicroRNA Regulation of Atherosclerosis.Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansAltered DNA methylation in neonates born large-for-gestational-age is associated with cardiometabolic risk in children.Pharmacogenomics, lipid disorders, and treatment options.Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.Lipoprotein(a) as a therapeutic target in cardiovascular disease.Investigational therapies for the treatment of atherosclerosis.Emerging therapeutic approaches to treat dyslipidemia.Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.Looking into the crystal ball-upcoming drugs for dyslipidemia.AAV-mediated gene therapy for atherosclerosis.Emerging drugs for hyperlipidaemia: an update.The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.Gene-targeting pharmaceuticals for single-gene disorders.Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.Cardiovascular Gene Therapy: Past, Present, and Future.Injection site reactions after subcutaneous oligonucleotide therapyProgress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.
P2860
Q26741705-7ED04009-C0B3-4D3A-951C-5D4415553CDCQ26771862-C4789C7D-7E47-44B5-B3EE-879DCA2D3F25Q26782522-B63DA7E2-995E-40A1-BDD5-228F526F4661Q26830297-BD9E4105-339A-47E4-8D56-E25F7A922EC5Q30833167-5893CED4-C62B-4825-B6AE-F060B534EF96Q33705462-95BC8ECB-943B-49C8-85D3-8D23542C770DQ33758267-2802C9DD-620C-46E4-AC5E-145428D12AEEQ34297049-7C22C328-50CD-4F86-973E-D59F1BE8CA77Q34456562-48C1DF16-354A-444E-916F-B5160618FE49Q34718630-E4008A67-5488-4C64-8D8B-D2976A60FEAFQ35130714-01DEBFC8-2F01-41B7-A5CA-50FA544C7EB5Q35132715-3E5276C5-5FE6-488C-9BF1-A59D8CE3EA51Q35447178-51446C22-E6B9-4531-9B9C-9F8B315E603EQ35645239-2F5BCF95-6D89-4619-8BF7-75C86568B6C0Q35723980-0520C11F-D5C9-4FC0-955F-9D3958362E86Q35756629-2675B8D4-3533-4F49-8624-3E45F7713CE4Q35803568-9DE04883-85C5-41C4-8126-8EA1D2EFBEAEQ36051650-214EFFCA-5886-47F8-B5AC-0BD805F901F9Q36106490-D7B75391-8C4E-4549-8FC2-DF50BBCC6399Q36233117-0B805E2C-F3BA-4E2B-8C93-AF675832947EQ36296212-F6EE80FE-1B04-4AE0-917C-361FF4BAA32AQ36602813-19F35242-8724-4401-BA91-DF64DEE979B5Q36617508-6070AF1B-2379-451A-85C7-B207E7E6C28AQ37699269-64E928C0-FBEC-4470-9D0D-AA13D32B1483Q38203774-22FBA948-BFA2-4AF4-828F-1130C9629314Q38207925-33C96920-346B-4A2E-B0BF-A44CBCF966D6Q38213476-C35307E7-B1D3-4A6B-936E-093EECF58297Q38214386-90AD32CC-0667-4E08-8038-4EB5BF38C656Q38217102-83155BA7-E959-4251-A299-C43A5356261EQ38229839-8FA964F4-AFED-4655-822F-2AD7ECA4EB75Q38235611-8D99337E-6BFF-42F9-AB9F-19035AF1D072Q38236204-4D6DABFB-AA5B-4028-85C9-3AC1182054DCQ38263909-900EA9CF-6119-4C77-BED7-D82D0441F05EQ38268342-6E56CEA0-B4E1-446C-9341-A39909E08DFDQ38325807-1DDF98A2-06B3-4B36-8D33-F0849166B829Q38656342-C53C68FA-15A9-4A03-ADEF-BB0C4C74644BQ38673894-9810E373-2D56-4C6A-8326-D1A6CAF8ED2BQ38733395-F3170843-295B-4BFB-A7E0-B0C04525E058Q38803235-09124FAB-DFFE-47CB-91F8-B1D9B843C5D1Q38839105-145C0AA0-1A41-4CC2-9C04-5EA3DB97DC77
P2860
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@en
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@nl
type
label
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@en
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@nl
prefLabel
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@en
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1476
Mipomersen, an apolipoprotein ...... ind, placebo-controlled trial.
@en
P2093
Gregory S Thomas
JoAnn D Flaim
Michael Davidson
Shariq Ali
P304
P356
10.1016/J.JACC.2013.07.081
P407
P577
2013-09-04T00:00:00Z